Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children

Pediatric Transplantation

Volumn 7, Issue 2, 2003, Pages 130-136

  Svennilson, Johan ^a,b   Remberger, Mats ^b   Ringdén, Olle ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ABO blood group system; Acute graft vs. host disease; GVHD prophylaxis; Hematopoietic stem cell transplantation; Risk factors

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN; METHOTREXATE;

ADOLESCENT; ALLOTRANSPLANTATION; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PROPHYLAXIS; RISK FACTOR; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0346658324     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00030.x     Document Type: Article

References (30)

1. RINGDÉN O, DEEG H-J. Clinical spectrum of graft-versus-host disease. In: FERRARA JLM, DEEG HJ, BURAKOFF S, eds. Graft vs. Host Disease, New York: Marcel Dekker, Inc., 1996, pp. 525-559.
2. RINGDÉN O, HERMANS J, LABOPIN M, APPERLEY J, GORIN NC, GRATWOHL A for the Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia and Lymphoma 1996: 24: 71-79.
3. WEIDEN PL, FLOURNOY N, THOMAS ED, et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979: 300: 1068-1073.
4. TRUITT RL, JOHNSON BD, MCCABE CM, WEILER MB. Graftversus-leukemia. In: FERRARA JLM, DEEG HJ, BURAKOFF S, eds. Graft vs. Host Disease. New York: Marcel Dekker, Inc., 1996, pp. 385-423.
5. WEIDEN PL, SULLIVAN KM, FLOURNOY N, STORB R, THOMAS ED. Antileukemic effect of chronie graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529-1533.
6. HOROWITZ MM, GALE RP, SONDEL PM, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood 1990: 75: 555-562.
7. WEISDORF D, HAKKE R, BLAZAR B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991: 51: 1197-1203.
8. HASSAN Z, LJUNGMAN P, RINGDÉN O, et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001: 27: 479-485.
9. RINGDÉN O, PIHLSTEDT P, MARKLING L, et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991: 7: 221-226.
10. OAKHILL A, PAMPHILON DH, POTTER MN, et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastie leukaemia in second complete remission. Br J Haematol 1996: 94: 574-578.
11. REMBERGER M. SVAHN B-M, HENTSCHKE P. LÖFGREN C, RINGDÉN O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999: 24: 823-830.
12. RINGDÉN O, GROTH C-G, ASCHAN J, et al. Bone marrow transplantation for metabolic disorders at Huddinge Hospital. Transplant Proc 1990: 22: 198-202.
13. THOMAS ED, STORB R, CLIFT RA, et al. Bone-marrow transplantation. Parts I and II. N Engl J Med 1975: 292: 832-843, 895-902.
14. RINGDÉN O, BÄCKMAN L, LÖNNQVIST B, et al. A randomized trial comparing use of cyclosporin and methotrexate for graftversus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. Bone Marrow Transplant 1986: 1: 41-51.
15. STORB R, DEEG HJ, WHITEHEAD J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729-735.
16. ASCHAN J, RINGDÉN O, ANDSTRÖM E, LJUNGMAN P, LöNNQVIST B. REMBERGER M. Individualized prophylaxis against graftversus-host disease in leukemic marrow transplant recipients. Bone Marrow transplant 1994: 14: 79-87.
17. PRZEPIORKA D, WEISDORF D, MARTIN P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995: 15: 825-828.
18. MAYER G, WERNET D, NORTHOFF H, SCHNEIDER W. A simple technique for red blood cell removal in major ABO-incompatible bone marrow transplantation. Vox Sang 1994: 66: 112-116.
19. BRESLOW N, DAY N, DAVIS W. The analysis of case-control studies. In: Statistical Methods in Cancer Research. Vol. 1. Lyon: IARC Sci Publ., 1980, pp. 5-338.
20. RINGDÉN O, HOROWITZ MM, SONDEL P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993: 81: 1094-1101.
21. LEVINE JE, WILEY J, KLETZEL M, et al. Cytokinemobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant 2000: 25: 13-18.
22. BACIGALUPO A, VAN LINT MT, OCCHINI D, et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988: 45: 1091-1094.
23. GALE RP, FEIG S, HO WG, FALK P, RIPPEE C, SPARKES R for the UCLA Marrow Transplant Team. ABO blood group system and bone marrow transplantation. Blood 1977: 50: 185-194.
24. BUCKNER CD, CLIFT RA, SANDERS JE, et al. ABO-incompatible marrow transplants. Transplantation 1978: 26: 233-238.
25. CURTIS JE, MESSNER HA. Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility. Can Med Assoc J 1982: 126: 649-655.
26. TAN P, ONG YW, TIEN SL, LOH TF, LIM ST. A preliminary report on ABO incompatible bone marrow transplant. Ann Acad Med Singapore 1991: 20: 421-428.
27. WIESNETH M, HERTENSTEIN B, BUNJES D, et al. ABO-incompatible bone marrow transplantation. Beitrage zur Infusionstherapie 1992: 30: 354-358.
28. MIELCAREK M, LEISENRING W, TOROK-STORB B, STORB R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000: 96: 1150-1156.
29. STUSSI G, SEEBACH L, MUNTWYLER J, SCHANZ U, GMUR J, SEEBACH JD. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. Br J Haematol 2001: 113: 251-253.
30. ATKINSON K, FARRELL C, CHAPMAN G, DOWNS K, PENNY R, BIGGS JC. Female marrow donors increase the risk for acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986: 63: 231-239.